PT  - JOURNAL ARTICLE
AU  - Agusti, Alvar
AU  - Rapsomaniki, Eleni
AU  - Beasley, Richard
AU  - Hughes, Rod
AU  - Müllerová, Hana
AU  - Papi, Alberto
AU  - Pavord, Ian D
AU  - Faner, Rosa
TI  - Treatable traits in the NOVELTY study: prevalence, patterns and relationship with physician-assessed severity
AID  - 10.1183/13993003.congress-2021.OA1289
DP  - 2021 Sep 05
TA  - European Respiratory Journal
PG  - OA1289
VI  - 58
IP  - suppl 65
4099  - http://erj.ersjournals.com/content/58/suppl_65/OA1289.short
4100  - http://erj.ersjournals.com/content/58/suppl_65/OA1289.full
SO  - Eur Respir J2021 Sep 05; 58
AB  - Introduction: NOVELTY is a global, prospective, observational study collecting real-world data from patients with physician-assigned asthma and/or COPD (NCT02760329). The presence of treatable traits (TTs) may be a useful way to stratify these patients.Aims: To describe the prevalence, patterns and relationship with physician-assessed severity of 30 TTs of potential clinical relevance, selected by expert consensus, in patients with asthma and/or COPD in NOVELTY.Methods: This analysis included 5,932 patients with asthma, 1,396 with asthma+COPD and 3,898 with COPD from NOVELTY. Severity of asthma and/or COPD was physician-assessed.Results: The mean (±SD) number of TTs per patient was 15.3±8.7 in asthma, 21.4±9.5 in asthma+COPD and 18.0±8.7 in COPD. The figure presents the age-adjusted prevalence of the 30 TTs considered in this analysis (red, pulmonary; green, extra-pulmonary; blue, behavioural/environmental factors), ordered from highest to lowest in patients with asthma, and shows that the prevalence and pattern of TTs was different between asthma and COPD and intermediate in asthma+COPD. TT patterns also varied in severe disease; asthma+COPD was more like COPD than asthma.Conclusions: (1) TTs were prevalent across asthma and/or COPD diagnoses in a real-world setting; (2) The patterns of TTs varied between asthma, asthma+COPD and COPD overall, and in patients with severe disease.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, OA1289.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).